58. 肥大型心筋症 ［臨床試験数：92，薬物数：126（DrugBank：35），標的遺伝子数：40，標的パスウェイ数：141］
Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||NCT01556568||February 2012||15/3/2012||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy||An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy||Cardiomegaly||Drug: MEK162||Array Biopharma, now a wholly owned subsidiary of Pfizer||NULL||Withdrawn||18 Years||65 Years||All||0||Phase 2||United States;United Kingdom|
|2||EUCTR2011-003392-10-GB||23/01/2012||24/08/2011||A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients.||An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy.||Noonan syndrome hypertrophic cardiomyopathy |
MedDRA version: 14.1Level: PTClassification code 10029748Term: Noonan syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 14.1Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
|Product Code: MEK162||Novartis Pharma Services AG||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|
|22||United Kingdom;United States|